Announcements Trials

Browse Landscape

Phase

Phase 3 3 Phase 2 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 31 Carboplatin 24 Specimen Handling 19 Magnetic Resonance Spectroscopy 17 Cyclophosphamide 17 Nivolumab 14 Dexamethasone 14 Bevacizumab 13 fludarabine 12 atezolizumab 11 Temozolomide 11 Gemcitabine 11 Biopsy 11 Paclitaxel 10 venetoclax 9 Pemetrexed 9 Ipilimumab 9 Cisplatin 8 Rituximab 7 Prednisone 7 Oxaliplatin 7 Lenalidomide 7 Fluorouracil 7 Docetaxel 7 Capecitabine 7 olaparib 6 Vincristine 6 Leucovorin 6 patritumab deruxtecan 5 lenvatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ontruzant × 30 days × Clear all

NCT06686394 2026-05-22

MK-1022-009

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡